stella
beta
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas — Stella
Recruiting
Back to Recurrent Malignant Glioma trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio
View full record on ClinicalTrials.gov